Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZARUX for AEL: Azacitidine plus ruxolitinib in AML/MDS with erythroid predominance or JAK-STAT abnormalities
jRCTs051240090Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine and ruxolitinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Novartis. Primary endpoint: Maximum tolerated dose. Started Aug 2024; status: recruiting.
02
Drugs
azacitidineruxolitinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs051240090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240090.